Provectus Biopharmaceuticals Inc.

351 articles about Provectus Biopharmaceuticals Inc.

• Investigation Finds Ex-Provectus CEO Did Not Produce Travel Documentation, May Have Altered Receipts

  3/16/2016

• Provectus To Host Fourth Quarter, Year-End 2015 Conference Call Wednesday, March 16, 2016, At 4 PM EDT

  3/11/2016

• Provectus Changes Date Of Quarterly Business Update Conference Call To Wednesday March 16, 2016, At 4 Pm (EDT)

  3/10/2016

• Provectus To Host Business Update Conference Call Tuesday, March 1, 2016, At 4 PM EST

  3/1/2016

• Provectus Awarded Patent Extending Protection Of The PV-10 Manufacturing Process

  3/1/2016

• Provectus Initiating Phase 1 Study Of PV-10 In Neuroendicrine Tumors Metastatic To Liver

  2/29/2016

• Provectus Co-Founder and CEO and Steps Down Due to Personal and Health Reasons

  2/29/2016

• Provectus Announces Leadership Changes

  2/29/2016

• Provectus Biopharmaceuticals Inc. Announces Data On PV-10 And Co-Inhibitory Blockade To Be Presented At AACR Annual Meeting 2016

  2/24/2016

• Provectus Biopharmaceuticals Inc. To Host Fourth Quarter, Year-End 2015 Conference Call Thursday, March 10, 2016, At 4 PM EST

  2/10/2016

• Data On Immunology Effects Of Provectus Biopharmaceuticals Inc. PV-10 In Colon Cancer Presented At 11th Annual ASC Meeting

  2/3/2016

• Provectus Biopharmaceuticals Inc. To Present At 18th Annual BIO CEO & Investor Conference

  2/2/2016

• Provectus Biopharmaceuticals Inc. Announces Immunology Data On PV-10 In Colon Cancer To Be Presented At 11th Annual ASC Meeting

  1/22/2016

• Provectus Biopharmaceuticals Inc. Confirms First Patients Dosed In Trials Of PV-10 For Melanoma

  1/12/2016

• Provectus Biopharmaceuticals Inc. To Present At Biotech Showcase 2016 On Wednesday January 13, 2016 At 3:30 PM Pacific Time

  12/16/2015

• Provectus Biopharmaceuticals Inc. Reports Immune Mechanism Of Action Data For Pv-10 Presented At Society For Immunotherapy Of Cancer Annual Meeting Authored By Researchers At Moffitt Cancer Center

  11/6/2015

• Provectus Biopharmaceuticals Inc. Reports Third Quarter 2015 Financial Results

  11/5/2015

• Provectus Biopharmaceuticals Inc. Will Hold Its 2015 Third Quarter Business Update Conference Call On Thursday, November 5, 2015, At 5 PM Eastern Standard Time

  10/20/2015

• Provectus Biopharmaceuticals Inc. Reports Publication Of Review Paper On PV-10 Tumor Ablation And Immune Stimulation

  9/29/2015

• Provectus Biopharmaceuticals Inc. Announces Initiation Of Phase Ib/II Clinical Trial To Study PV-10 In Combination With Immune Check Point Inhibitor Pembrolizumab

  9/23/2015